1,040 results match your criteria Clinical Colorectal Cancer[Journal]


Pattern, Stage, and Time of Recurrent Colorectal Cancer After Curative Surgery.

Clin Colorectal Cancer 2019 Jan 29. Epub 2019 Jan 29.

Head Surgery Unit, Clinical Sciences Department, College of Medicine University of Sharjah, Sharjah, United Arab Emirates. Electronic address:

Surgery remains the mainstay of curative treatment for colorectal cancer (CRC). Despite curative surgery, some patients experience cancer recurrence. However, the pattern, stage, and time of recurrent disease (RD) remain unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2019.01.003DOI Listing
January 2019

Disqualification of Neoadjuvant Rectal Score Based on Data of 6596 Patients From the Netherlands Cancer Registry.

Clin Colorectal Cancer 2019 Jan 19. Epub 2019 Jan 19.

Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands; Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address:

Background: The neoadjuvant rectal score (NAR) was developed as a surrogate endpoint for overall survival in patients with rectal cancer after neoadjuvant treatment. We aimed to validate the NAR score in patients from the Netherlands Cancer Registry database.

Patients And Methods: We studied patients with rectal cancer treated with long-course neoadjuvant therapy followed by surgery in the Netherlands between 2007 and 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2019.01.001DOI Listing
January 2019

Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial.

Clin Colorectal Cancer 2019 Jan 3. Epub 2019 Jan 3.

Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, Australia; University of Adelaide, Adelaide, Australia; Basil Hetzel Institute, Woodville, Australia.

Background: For metastatic colorectal cancer, previous reports have described differences in biology and outcome, including response to biologic agents, based on whether the primary tumor is right- or left-sided. We explored the molecular markers from the AGITG MAX trial.

Patients And Methods: The AGITG MAX trial was a randomized study comparing capecitabine versus capecitabine + bevacizumab versus capecitabine + bevacizumab + mitomycin C as first-line therapy in advanced colorectal cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.12.002DOI Listing
January 2019
2.907 Impact Factor

Trends in Colorectal Cancer Incidence and Survival in Iowa SEER Data: The Timing of It All.

Clin Colorectal Cancer 2018 Dec 22. Epub 2018 Dec 22.

National Institute of Environmental Health Sciences, Durham, NC.

Background: Colorectal cancer (CRC) is common worldwide, with 140,250 diagnoses and 50,630 deaths estimated for the United States in 2018. Guidelines current to the most recent individuals in our analysis suggested regular screenings beginning at age 50 have reduced the incidence of CRC. However, the incidence continues to rise among those under 50. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.12.001DOI Listing
December 2018

Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.

Clin Colorectal Cancer 2018 Dec 28. Epub 2018 Dec 28.

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada. Electronic address:

Purpose: To evaluate the impact of sex on toxicity and efficacy outcomes among patients with metastatic colorectal cancer receiving first-line 5-fluorouracil-based regimens.

Patients And Methods: A pooled analysis of data sets from 5 clinical trials (NCT00115765, NCT00364013, NCT00272051, NCT00305188, NCT00384176) was performed. Kaplan-Meier analysis and log-rank testing were used to assess the differences in overall and progression-free survival between male and female subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.12.006DOI Listing
December 2018
2.907 Impact Factor

Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer.

Clin Colorectal Cancer 2018 Dec 27. Epub 2018 Dec 27.

Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey. Electronic address:

Background: In the present study, we investigated the prognostic and predictive role of neuroendocrine differentiation (NED) and tumor-associated macrophage (TAM) infiltration in tumor tissue from patients with advanced colorectal cancer who had received bevacizumab plus chemotherapy.

Patients And Methods: A total of 123 consecutive patients with advanced colorectal cancer who had received bevacizumab plus irinotecan/oxaliplatin-based combination chemotherapy were included in the present study. In addition to the clinicopathologic parameters, the presence of NED and the level of TAM infiltration were studied as covariates for survival analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.12.004DOI Listing
December 2018
1 Read

Neuroendocrine Differentiation, Microsatellite Instability, and Tumor-infiltrating Lymphocytes in Advanced Colorectal Cancer With BRAF Mutation.

Clin Colorectal Cancer 2018 Dec 20. Epub 2018 Dec 20.

Unit of Pathology, Department of Medicine and Surgery, University of Insubria, Varese, Italy; Research Center for the Study of Hereditary and Familial Tumors, Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Background: Approximately 10% of metastatic colorectal cancer (mCRC) cases will harbor the BRAF p.V600E mutation (BRAF-mCRC) and have been associated with a poor prognosis. Although they are usually considered a unique clinical entity, biologic heterogeneity has been described. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183043
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.12.003DOI Listing
December 2018
6 Reads

Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.

Clin Colorectal Cancer 2018 Nov 29. Epub 2018 Nov 29.

Univ Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, Bordeaux, France; Bordeaux PharmacoEpi, INSERM CIC1401, Bordeaux, France; CHU de Bordeaux, Pôle de Sante publique, Service de Pharmacologie médicale, Bordeaux, France.

Background: Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and frail patients. The aim was to describe use, safety, and effectiveness of targeted therapies in first-line mCRC treatment according to age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.11.005DOI Listing
November 2018
2 Reads

Review: Pathology and Its Clinical Relevance of Mucinous Appendiceal Neoplasms and Pseudomyxoma Peritonei.

Clin Colorectal Cancer 2018 Dec 6. Epub 2018 Dec 6.

Department of Pathology, Laboratory for Pathology and Medical Microbiology (PAMM), Eindhoven, the Netherlands.

Until recently, many classifications existed for the terminology and histopathologic classification of appendiceal mucinous neoplasms, mucinous appendiceal adenocarcinomas, and pseudomyxoma peritonei (PMP). A major accomplishment was achieved by consensus-based histopathologic classifications on behalf of the Peritoneal Surface Oncology Group International regarding mucinous appendiceal tumours and PMP. As different classifications were used over the years and also owing to the rare nature of these tumors, many clinicians are not familiar with the terminology and the impact on patient management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.11.007DOI Listing
December 2018
1 Read

Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.

Clin Colorectal Cancer 2018 Nov 16. Epub 2018 Nov 16.

Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University Vienna, Vienna, Austria. Electronic address:

An increasing number of patients with metastatic colorectal cancer (mCRC) are able to receive 3 or more lines of therapy. Treatments in this setting can include regorafenib (an oral multikinase inhibitor), trifluridine/tipiracil hydrochloride (TAS-102), antibodies that target epidermal growth factor receptor for patients with RAS wild-type tumors (if no prior exposure), and, where approved, anti-programmed cell death protein 1 inhibitors for patients with microsatellite instability-high mCRC. Although guidelines describe the available treatment options, few insights are provided to guide selection and sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.11.002DOI Listing
November 2018
1 Read

Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20.

Clin Colorectal Cancer 2018 Nov 28. Epub 2018 Nov 28.

Canadian Cancer Trials Group, Kingston, Canada.

Background: The safety and efficacy of targeted therapy in older patients (≥ 70 years) with metastatic colorectal cancer is not well evaluated.

Patients And Methods: Outcomes of older patients (including overall survival [OS], progression-free survival [PFS], toxicity, and quality of life [QoL]) were compared to young patients using data from 2 large previously reported clinical trials, CO.17 (cetuximab vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.11.006DOI Listing
November 2018
2 Reads
2.907 Impact Factor

Pathologic Staging Inconsistency Between ypT4N0 (stage II) and ypT1-2N1 (stage III) After Preoperative Chemoradiotherapy and Total Mesorectal Excision in Rectal Cancer: A Multi-Institutional Study.

Clin Colorectal Cancer 2018 Nov 23. Epub 2018 Nov 23.

Department of Radiation Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Background: In the Surveillance, Epidemiology, and End Results population-based data, the survival curves reversed between T4N0 (stages IIB or IIC) and T1-2N1 (stage IIIA) in rectal cancer. However, T4N0 had a higher stage than T1-2N1 in the current colorectal staging system.

Patients And Methods: We analyzed 1804 patients with rectal cancer who were treated with preoperative chemoradiotherapy and curative surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.11.003DOI Listing
November 2018
1 Read

Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases.

Clin Colorectal Cancer 2018 Nov 24. Epub 2018 Nov 24.

Oncology and Hemato-Oncology Department, University of Milan, Milan, Italy; General Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Background: In colorectal cancer liver metastases (CRCLM), bevacizumab-based neoadjuvant strategies provide increased pathologic response. We aimed at assessing the activity of perioperative capecitabine, oxaliplatin, irinotecan, and bevacizumab (COI-B regimen) in patients with potentially resectable CRCLM, and investigating biomarkers for early prediction of pathologic response.

Patients And Methods: This was a single-center phase II study enrolling patients with liver-limited, borderline resectable disease and/or high-risk features. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.11.004DOI Listing
November 2018
2 Reads

Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.

Clin Colorectal Cancer 2018 Nov 16. Epub 2018 Nov 16.

Department of Medical Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada. Electronic address:

Background: First-line adjuvant chemotherapy options for early-stage colorectal cancer (CRC) include CapeOx (capecitabine, intravenous oxaliplatin) and FOLFOX (intravenous 5-fluorouracil, leucovorin, oxaliplatin). Capecitabine is an oral prodrug analog of 5-fluorouracil, and recent studies have suggested that proton pump inhibitors (PPIs) may detrimentally affect capecitabine efficacy. Conversely, some literature suggests that PPIs may negatively affect CRC itself. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183045
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.11.001DOI Listing
November 2018
11 Reads
2.907 Impact Factor

5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer.

Clin Colorectal Cancer 2018 Nov 1. Epub 2018 Nov 1.

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada. Electronic address:

Background: 5-Fluorouracil (5-FU) represents the backbone of systemic therapy regimens of colorectal cancer. The current study aims at evaluating the patterns and predictors of cardiac adverse events associated with various 5-FU-based systemic therapy regimens among patients with metastatic colorectal cancer.

Materials And Methods: This pooled analysis includes de-identified patient-level datasets from 5 randomized studies (NCT00272051, NCT00305188, NCT00115765, NCT00364013, and NCT00384176). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.10.006DOI Listing
November 2018
10 Reads
2.907 Impact Factor

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.

Clin Colorectal Cancer 2018 12 8;17(4):313-319. Epub 2018 Jun 8.

Department of Oncology, Monash Health and Monash University, Clayton, Victoria, Australia.

Background: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation (ICECREAM) study assessed the efficacy of cetuximab monotherapy compared with cetuximab combined with chemotherapy for quadruple wild-type (KRAS, NRAS, BRAF, or P13KCA exon 20) metastatic colorectal cancer.

Patients And Methods: Patients were enrolled in an open-label, multicenter, phase II trial and randomly assigned to cetuximab 400 mg/m, then 250 mg/m cetuximab weekly, with or without irinotecan 180 mg/m every 2 weeks. The primary endpoint was 6-month progression-free survival; secondary endpoints were response rate, overall survival, toxicity, and quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.06.002DOI Listing
December 2018
18 Reads
2.907 Impact Factor

Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment.

Clin Colorectal Cancer 2018 Oct 24. Epub 2018 Oct 24.

Danish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.

Background: RAS and RAF mutations in colorectal cancer (CRC) hold value in precision medicine. Liquid biopsy is an alternative to tumor tissue biopsy, and circulating tumor DNA (ctDNA) has been intensively investigated, but the clinical relevance of RAS and RAF mutations in plasma is yet to be determined. This study aimed to investigate the clinical aspects of RAS/RAF mutations during combination treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.10.004DOI Listing
October 2018
13 Reads

Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER-Based Analysis.

Clin Colorectal Cancer 2018 Oct 27. Epub 2018 Oct 27.

Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address:

Background: The prognostic value of tumor sidedness in metastatic colorectal cancer (CRC) has been established, but its impact on nonmetastatic disease remains unclear. Our study aimed to explore the prognostic effect of tumor sidedness by subgroup survival analyses, according to histology and tumor grade in stage I-IV CRCs.

Methods: A retrospective population-based study was conducted based on Surveillance, Epidemiology and End Results (SEER) data. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183045
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.10.005DOI Listing
October 2018
13 Reads

Rising Proportion of Young Individuals With Rectal and Colon Cancer.

Clin Colorectal Cancer 2018 Oct 17. Epub 2018 Oct 17.

Division of Colon and Rectal Surgery, Mayo Clinic, Jacksonville, FL.

Background: Recent trends have identified increasing number of young individuals with rectal and colon cancers. These individuals, who are younger than 50 years old, in most instances would not meet screening guidelines. We aimed to report the characteristics and trend of the rising proportion of young individuals being diagnosed with rectal and colon cancers at our institutions. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183040
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.10.002DOI Listing
October 2018
12 Reads

Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016.

Clin Colorectal Cancer 2018 Oct 16. Epub 2018 Oct 16.

Department of Registration, Cancer Registry of Norway, Oslo, Norway.

Background: Anal squamous cell carcinoma (ASCC) is a rare, human papilloma virus-associated cancer. The purpose was to investigate the population-based incidence rates, age and gender distribution, and survival of ASCC.

Materials And Methods: All primary ASCC in 1987 to 2016 were identified in the Cancer Registry of Norway (N = 1548), with information on age, gender, stage, county of residence, radiotherapy, and survival. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183030
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.10.001DOI Listing
October 2018
8 Reads

E-Cadherin in Colorectal Cancer: Relation to Chemosensitivity.

Clin Colorectal Cancer 2018 Oct 16. Epub 2018 Oct 16.

Privolzhsky Research Medical University (PRMU), Nizhny Novgorod, Russia.

Background: The conventional chemotherapy of colorectal cancer with irinotecan, 5-fluorouracil, and oxaliplatin remains one of the front-line treatments worldwide. However, its efficacy is quite low. Recently studies of the epithelial-mesenchymal transition (EMT) have become the focus of investigations into the cause of chemoresistance in several types of cancer, including colorectal cancer. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028173049
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.10.003DOI Listing
October 2018
10 Reads

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.

Clin Colorectal Cancer 2018 Oct 19. Epub 2018 Oct 19.

Sorbonne Paris Cité, Paris Decartes University; Hôpital Européen Georges-Pompidou, Paris, France.

Background: According to the IDEA trial, 6-month adjuvant chemotherapy should remain the treatment standard in stage III T4 or N2 colon cancer. The relatively poor survival in this high-risk subgroup-a 3-year disease-free survival (DFS) rate of 65%-and the potential synergistic efficacy of 5-fluorouracil (5-FU), oxaliplatin, and irinotecan suggest that FOLFIRINOX may be a regimen of particular interest in this setting.

Patients And Methods: This multicenter international phase 3 trial (ClinicalTrials. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183025
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.09.011DOI Listing
October 2018
12 Reads

Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.

Clin Colorectal Cancer 2018 Sep 29. Epub 2018 Sep 29.

Department of Medicine, GI and Lymphoma Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, UK. Electronic address:

Background: Gastrointestinal (GI) cancer patients may not be considered for therapy with fluoropyrimidines (FPs) because of previous cardiovascular (CV) toxicity or preexisting risk factors; such patients may benefit from raltitrexed-based therapy.

Patients And Methods: Patient, tumor, and treatment characteristics, as well as clinical outcomes of all consecutively treated patients with raltitrexed at the Royal Marsden Hospital between October 1998 and July 2011 were examined. GI cancer patients who developed CV toxicity as a result of FPs and those with significant CV risk factors receiving raltitrexed were included in this analysis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183021
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.09.010DOI Listing
September 2018
7 Reads

Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.

Clin Colorectal Cancer 2018 Oct 10. Epub 2018 Oct 10.

Department of Medical Oncology, Mayo Clinic, Rochester, MN.

Introduction: Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU. Given the additional benefit of oxaliplatin over FP alone in the management of colorectal cancer, retaining oxaliplatin in the treatment regimen is desirable, but the safety of combining bolus 5-FU with oxaliplatin in patients with FP-induced vasospasm is not well established. We performed a retrospective review to explore the safety of substituting FLOX (bolus 5-FU, oxaliplatin, leucovorin) for FOLFOX (infusional 5-FU, oxaliplatin, leucovorin) and CAPOX (capecitabine, oxaliplatin) in patients who had FP-induced coronary vasospasm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.09.006DOI Listing
October 2018
1 Read

Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.

Clin Colorectal Cancer 2018 Sep 21. Epub 2018 Sep 21.

Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address:

Introduction: The programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis plays an important role in controlling immune suppression by down-regulating T effector cell activities, enabling tumor cells to escape from the host's antitumor immunsurveillance. While only a small part of colon cancer cells express PD-L1, we sought to evaluate the differential impact of stromal and epithelial PD-L1 expression of primary tumors and liver metastasis on overall survival (OS) in colon cancer patients.

Patients And Methods: Using a next-generation tissue microarray approach, we assessed both epithelial and stromal PD-L1 expression levels in primary tumors (n = 279) and corresponding liver metastases (n = 14) of colon cancer patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183008
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.09.007DOI Listing
September 2018
13 Reads

Measurement of the IgM and IgG Autoantibody Immune Responses in Human Serum has High Predictive Value for the Presence of Colorectal Cancer.

Clin Colorectal Cancer 2018 Sep 27. Epub 2018 Sep 27.

Applied Biochemistry Group, School of Biotechnology, Dublin City University, Dublin, Ireland; Research Complex, Hamad Bin Khalifa University, Education City, Doha, Qatar. Electronic address:

Introduction: Colorectal cancer is a major public health issue, with incidences continuing to rise owing to the growing and aging world population. Current screening strategies for colorectal cancer diagnosis suffer from various limitations, including invasiveness and poor uptake. Consequently, there is an unmet clinical need for a minimally invasive, sensitive, and specific method for detecting the presence of colorectal cancer and pre-malignant lesions. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183027
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.09.009DOI Listing
September 2018
9 Reads

Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.

Clin Colorectal Cancer 2018 Aug 20. Epub 2018 Aug 20.

Division Hematology/Oncology Case, Department of Medicine, MetroHealth Cancer Center, Western Reserve University, Cleveland, OH.

Introduction: Fluoropyrimidines (FPDs) are a fundamental component of many chemotherapy regimens. Cardiotoxic adverse events (AEs) such as angina, ischemia, arrhythmias, and cardiomyopathy associated with 5-fluorouracil (5-FU) and capecitabine (CAPE) have been sparingly described in studies, primarily through case reports. Data from the 1990s revealed an estimated incidence of 0. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183034
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.08.001DOI Listing
August 2018
8 Reads

Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials.

Clin Colorectal Cancer 2018 Sep 27. Epub 2018 Sep 27.

Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada. Electronic address:

Background: Baseline albumin-bilirubin (ALBI) score has been shown to be a reliable prognostic predictor among patients with hepatocellular carcinoma. The current study aims at evaluating its prognostic impact among patients with colorectal liver metastases treated with first-line systemic therapy.

Materials And Methods: Through the Project Data Sphere portal, de-identified clinical trial datasets of 2 clinical trials (NCT00115765; PACCE [Panitumumab Advanced Colorectal Cancer Evaluation Study] trial) and (NCT00364013; PRIME [Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy] trial) were downloaded. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183040
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.09.008DOI Listing
September 2018
7 Reads
2.910 Impact Factor

FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.

Clin Colorectal Cancer 2018 Sep 21. Epub 2018 Sep 21.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

Background: Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.

Patients And Methods: We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy - essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin - in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183039
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.09.005DOI Listing
September 2018
2 Reads

ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer.

Clin Colorectal Cancer 2018 12 13;17(4):255-257. Epub 2018 Sep 13.

Department of Medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183043
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.09.001DOI Listing
December 2018
2 Reads

ACTH-Secreting Neuroendocrine Carcinoma of the Cecum: Case Report and Review of the Literature.

Clin Colorectal Cancer 2018 Aug 11. Epub 2018 Aug 11.

Division of Medical Oncology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. Electronic address:

Background: Approximately 30% of neuroendocrine tumors (NETs) present with secretory syndromes or develop one during the course of the disease. Cushing syndrome caused by a gastrointestinal tract NET is rare, with limited published information. We describe a patient with florid Cushing syndrome due to ectopic adrenocorticotropic hormone (ACTH) from a NET of colonic origin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.07.013DOI Listing
August 2018
4 Reads

Association Between Primary Payer Status and Survival in Patients With Stage III Colon Cancer: An National Cancer Database Analysis.

Clin Colorectal Cancer 2018 Sep 13. Epub 2018 Sep 13.

Creighton University School of Medicine, Omaha, NE.

Background: Colon cancer is the third most frequent cancer diagnosis, and primary payer status has been shown to be associated with treatment modalities and survival in cancer patients. The goal of our study was to determine the between-insurance differences in survival in patients with clinical stage III colon cancer using data from the National Cancer Database (NCDB).

Materials And Methods: We identified 130,998 patients with clinical stage III colon cancer in the NCDB diagnosed from 2004 to 2012. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183037
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.09.004DOI Listing
September 2018
2 Reads

Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases.

Clin Colorectal Cancer 2018 Sep 13. Epub 2018 Sep 13.

Department of Interventional Oncology/Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

Introduction: The purpose of this study was to identify predictors of overall (OS) and liver progression-free survival (LPFS) following Yttrium-90 radioembolization (RAE) of heavily pretreated patients with colorectal cancer liver metastases (CLM), as well as to create and validate a predictive nomogram for OS.

Materials And Methods: Metabolic, anatomic, laboratory, pathologic, genetic, primary disease, and procedure-related factors, as well as pre- and post-RAE therapies in 103 patients with CLM treated with RAE from September 15, 2009 to March 21, 2017 were analyzed. LPFS was defined by Response Evaluation Criteria In Solid Tumors 1. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183025
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.08.004DOI Listing
September 2018
5 Reads

Effects of Adjuvant Chemotherapy on Cognitive Function of Patients With Early-stage Colorectal Cancer.

Clin Colorectal Cancer 2018 Sep 13. Epub 2018 Sep 13.

Discipline of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil; Department of Oncology, AC Camargo Cancer Center, São Paulo, Brazil. Electronic address:

Purpose: Chemotherapy-related cognitive impairment can occur in cancer survivors after treatment, especially those patients who have undergone chemotherapy for breast cancer. The frequency and to what extent such toxicity develops in colorectal cancer (CRC) survivors is unknown. The present prospective study evaluated the effects of adjuvant chemotherapy on the cognitive performance of patients with localized CRC compared with a control group who had not undergone chemotherapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183036
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.09.002DOI Listing
September 2018
4 Reads

Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.

Clin Colorectal Cancer 2018 Sep 13. Epub 2018 Sep 13.

Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.

Background: Adenosine has an immunosuppressive and angiogenic modulation of the tumor microenvironment. The present study explored the efficacy of single nucleotide polymorphisms (SNPs) in adenosine-related molecules for patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy.

Patients And Methods: We analyzed genomic DNA extracted from 451 samples from 3 independent cohorts: a discovery cohort of 107 patients treated with FOLFIRI (5-fluorouracil, leucovorin, oxaliplatin, irinotecan) plus bevacizumab in FIRE-3 (ClinicalTrials. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15330028183038
Publisher Site
http://dx.doi.org/10.1016/j.clcc.2018.09.003DOI Listing
September 2018
2 Reads

Short-Course Radiotherapy in Neoadjuvant Treatment for Rectal Cancer: A Systematic Review and Meta-analysis.

Clin Colorectal Cancer 2018 12 11;17(4):320-330.e5. Epub 2018 Aug 11.

Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, People's Republic of China. Electronic address:

Background: To assess whether preoperative short-course radiotherapy (PSRT) could be the treatment of choice compared to preoperative long-course chemoradiotherapy (PLCRT) METHODS: The PubMed, Embase, and Web of Science Databases were searched to conduct a systematic review and meta-analysis. Perioperative and survival outcomes between PSRT and PLCRT were selected as end points for our meta-analysis. In addition, health-related quality-of-life outcomes were also systematically reviewed between PSRT and PLCRT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.07.014DOI Listing
December 2018
2 Reads
2.910 Impact Factor

Perioperative Management for Colorectal Peritoneal Metastases.

Clin Colorectal Cancer 2018 12 30;17(4):249-250. Epub 2018 Aug 30.

Department of Surgical Oncology, CHU Lyon Sud, Hospices Civils de Lyon, University of Lyon, Lyon, France; EMR 37-38, Lyon 1 University, Lyon, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.08.005DOI Listing
December 2018
1 Read

Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.

Clin Colorectal Cancer 2018 12 24;17(4):e751-e761. Epub 2018 Aug 24.

Keck School of Medicine, University of Southern California, Los Angeles, CA.

Background: Regorafenib and TAS-102 are standard treatment options in refractory metastatic colorectal cancer based on improvement in overall survival by 6 and 8 weeks, respectively, when compared with best supportive care alone (BSC). Given the small incremental clinical benefit, we evaluated their cost-effectiveness from a United States payer's perspective.

Materials And Methods: A Markov model was constructed to compare costs and effectiveness of regorafenib, TAS-102, and BSC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.08.003DOI Listing
December 2018
2 Reads

Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

Clin Colorectal Cancer 2018 12 23;17(4):e741-e749. Epub 2018 Aug 23.

Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.

Background: Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-related genes affect the NLR remain unclear.

Patients And Methods: In 77 patients with KRAS exon2 wild-type mCRC from prospective trials of first-line chemotherapy with cetuximab, expression levels of 354 immune-related genes were measured in tissue samples obtained from all patients by the HTG EdgeSeq Oncology Biomarker Panel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.08.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249067PMC
December 2018
3 Reads

Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.

Clin Colorectal Cancer 2018 12 17;17(4):e699-e709. Epub 2018 Jul 17.

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Background: The mucinous histologic subtype accounts for 5% to 20% of colorectal cancer (CRC) cases but remains poorly characterized. The present study characterized the baseline characteristics, mutational profile, and clinical outcomes of patients diagnosed with mucinous CRC.

Materials And Methods: We identified 1877 patients with metastatic CRC with available histologic findings and molecular profiling and summarized the baseline clinical and pathologic characteristics and overall survival (OS) stratified by the histologic type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.07.005DOI Listing
December 2018
5 Reads
2.910 Impact Factor

Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.

Clin Colorectal Cancer 2018 12 26;17(4):e719-e732. Epub 2018 Jul 26.

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Background: High thymidine kinase 1 (TK1) activity increases the incorporation of trifluridine (FTD) into DNA; thus, FTD antitumor activity is likely to increase in patients with high tumoral TK1 activity. To date, no established predictive biomarker to indicate the clinical benefit of FTD/tipiracil (TPI) has been identified. We aimed to determine the relationship between TK1 expression and FTD/TPI efficacy in refractory metastatic colorectal cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.07.009DOI Listing
December 2018
2 Reads

Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer.

Clin Colorectal Cancer 2018 12 4;17(4):e663-e669. Epub 2018 Jul 4.

Medical Oncology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.

Background: The aim of the present study was to evaluate the efficacy and safety of the combination of CAPOX-Bev (capecitabine [Cap] plus oxaliplatin and bevacizumab [Bev]), followed by maintenance Cap and Bev, for patients with metastatic colorectal cancer (mCRC) and aged > 75 years.

Patients And Methods: The regimen consisted of intravenous oxaliplatin 130 to 100 mg/m on day 1, oral Cap 750 to 1000 mg/m twice daily on days 1 to 14, and Bev 7.5 mg/kg on day 1, every 3 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.07.002DOI Listing
December 2018
2 Reads

Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.

Clin Colorectal Cancer 2018 12 29;17(4):e687-e697. Epub 2018 Jul 29.

Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan. Electronic address:

Background: Assessment of patient factors is essential for selecting later-line chemotherapy in patients with metastatic colorectal cancer (mCRC). The efficacy, prognosis, and safety of each treatment regimen according to nutritional and inflammatory status still remain to be elucidated.

Patients And Methods: A total of 550 patients with mCRC who were registered in the REGOTAS study (Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study, UMIN 000020416) and treated with trifluridine/tipiracil (TFTD) or regorafenib as a later-line therapy were retrospectively stratified according to the modified Glasgow Prognostic Score (mGPS), which divided patients into mGPS 0 to 2 by serum albumin and C-reactive protein, and compared. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.07.004DOI Listing
December 2018
4 Reads

Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal Cancer.

Clin Colorectal Cancer 2018 12 1;17(4):251-254. Epub 2018 Aug 1.

Department of Gastrointestinal Medical Oncology, National Cancer Center, Chuo-ku, Tokyo, Japan.

Continuation of anti-angiogenic agents beyond progression in second-line therapy is recognized as a standard of care for patients with metastatic colorectal cancer, and there are 3 options based on the results of the phase III trials: bevacizumab (ML18147 trial), ramucirumab (RAISE trial), and aflibercept (VELOUR trial). However, the eligibility criteria of these three trials differed, and there are no established biomarkers for selecting the optimal agent. In a collaborative study of the RAISE trial, it was reported that vascular endothelial growth factor (VEGF)-D may be a predictive marker for remucirumab, which can prevent binding of VEGF-D to VEGF receptor, and establishment of the standard method for assessing VEGF-D is eagerly awaited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.07.012DOI Listing
December 2018
2 Reads

Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study.

Clin Colorectal Cancer 2018 09 8;17(3):e601-e615. Epub 2018 Jun 8.

Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto, IRCCS, Padova, Italy. Electronic address:

Background: The impact of free triiodothyronine (FT)/free thyroxine (FT) ratio on survival in hospitalized geriatric patients was recently described. Up today, there are no data regarding the prognostic role of FT/FT ratio in patients with advanced cancer. We evaluated the impact of FT/FT ratio on survival in patients with refractory colorectal cancer (CRC) treated with regorafenib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.05.013DOI Listing
September 2018
16 Reads

Corrigendum.

Authors:

Clin Colorectal Cancer 2018 09;17(3):247

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.07.010DOI Listing
September 2018
2 Reads

Short-course Versus Long-course Neoadjuvant Therapy for Non-metastatic Rectal Cancer: Patterns of Care and Outcomes From the National Cancer Database.

Clin Colorectal Cancer 2018 12 26;17(4):297-306. Epub 2018 Jul 26.

Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL.

Introduction: The purpose of this study was to compare the utilization, pathologic response, and overall survival (OS) between long-course neoadjuvant chemoradiation (LC-CRT) and short-course neoadjuvant radiation (SC-RT) in the treatment of non-metastatic rectal cancer.

Methods And Materials: Retrospective data was obtained from the National Cancer Database (NCDB) for patients diagnosed with clinical stage II or III (limited to T3, any N or T1-2, N1-2) rectal cancer between 2004 and 2014 (28,193 patients). Univariate and multivariate analyses were performed to investigate factors associated with receipt of SC-RT, pathologic complete response (pCR) rate, and OS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.07.008DOI Listing
December 2018
2 Reads

Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.

Clin Colorectal Cancer 2018 12 25;17(4):e733-e739. Epub 2018 Jul 25.

Division of Hematology, Oncology and Palliative Care, St. Josef-Hospital Bochum, Ruhr-University, Bochum, Germany. Electronic address:

Introduction: Numerous trials have examined the prognostic and predictive value of localization of the primary tumor (LPT) in metastastic colorectal cancer, there is limited information about the predictive value of LPT on different maintenance strategies.

Materials And Methods: We analyzed progression-free survival (PFS)/overall survival (OS) on maintenance therapy according to LPT and mutational subgroups (BRAF/RAS) in patients from the AIO (Arbeitsgemeinschaft Internistische Onkologie) 0207 trial. Following induction, 471 patients were randomized to fluoropyrimidine (FU)/bevacizumab (Bev), Bev, or no treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.07.007DOI Listing
December 2018
3 Reads

Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial.

Clin Colorectal Cancer 2018 12 31;17(4):285-296. Epub 2018 Jul 31.

Department of Surgery, University Medical Center Regensburg, Regensburg, Germany; Department of Surgery, Krankenhaus Barmherzige Brüder Regensburg, Regensburg, Germany.

Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) as parts of an interdisciplinary treatment concept including systemic chemotherapy can improve survival of selected patients with peritoneal metastatic colorectal cancer (pmCRC). Nevertheless, the sequence of the therapeutic options is still a matter of debate. Thus, the COMBATAC (COMBined Anticancer Treatment of Advanced Colorectal cancer) trial was conducted to evaluate a combined treatment regimen consisting of preoperative systemic polychemotherapy + cetuximab followed by CRS + HIPEC and postoperative systemic polychemotherapy + cetuximab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.07.011DOI Listing
December 2018
6 Reads